Bubble contrast could reveal prostate cancer without a needle

NCT ID NCT05336786

Ongoing Diagnosis Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase III trial is testing whether a special ultrasound contrast agent, called Definity, can help doctors see prostate cancer on ultrasound images. The study involves 70 men scheduled for prostate removal surgery. Before surgery, they receive an IV of Definity, which contains tiny gas-filled bubbles that enhance ultrasound images. The goal is to see if this non-invasive method can accurately identify cancer sites in the prostate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Perflutren lipid microspheres (Definity)
What this could lead to: If successful, this could provide a non-invasive way to identify prostate cancer, potentially reducing the need for biopsies.
What could go wrong: This is a small, early-phase study with only 70 participants, and the technique may not be accurate enough to replace standard methods. The contrast agent also carries a small risk of allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CARCINOMA

Contacts and locations

Locations

Amsterdam University Medical Centers

Amsterdam, Netherlands
Sidney Kimmel Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.